sgs-742
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00093951)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- GABA-B receptor 1ANTAGONIST
GABBR1 antagonist
- GABA-B receptorANTAGONIST
GABA-B receptor antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCCP(=O)(O)CCCN- Mol. weight
- 179.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL112797 ↗
Also known as
- (3-aminopropyl)(n-butyl)phosphinic acid
- 3-aminopropyl-n-butyl phosphinic acid
- cgp36742
- cgp 36742
- cgp-36742
- sgs742
- sgs-742
- sgs-742
- sgs-742
- sgs-742
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02019667 | Phase 2 | Dec 10, 2013 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00093951 | Phase 2 | Apr 1, 2004 | Saegis Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2013 |
| Saegis Pharmaceuticals | For profit | 1 | 1 | 1 | 2004 |
2 organizations
Page 1 / 1